Pekka Allan Antero Mattila

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

TILT Biotherapeutics Oy is a preclinical stage company working in the field of cancer immunotherapy. It develops genetically modified oncolytic viruses that enhance T-cell therapies for cancer treatment. The company was founded by Akseli Hemminki in 2013 and is headquartered in Helsinki, Finland.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

Desentum Oy operates as a research-based biopharmaceutical firm that specializes in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens. The company was founded by Janne Jänis, Marja-Leena Laukkanen, Pekka Allan Antero Mattila, Merja Niemi, Anja Pallas, Juha Rouvinen, and Kristiina Takkinen in 2011 and is headquartered in Espoo, Finland.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

The company is part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has over 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings. Finnzymes, founded in 1986, is a leader in the development of PCR, quantitative real-time PCR, transposon and RNA technologies. Its aim is to develop products which make the difference, products that deliver results not achievable otherwise.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.